<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00877929</url>
  </required_header>
  <id_info>
    <org_study_id>1235.21</org_study_id>
    <secondary_id>2008-000874-19</secondary_id>
    <nct_id>NCT00877929</nct_id>
  </id_info>
  <brief_title>Telmisartan Fixed Dose Combination vs Amlodipine in Hypertensive Patients With Type 2 Diabetes Mellitus</brief_title>
  <official_title>An 8-week Randomised, Double-blind Study to Compare the Fixed-dose Combination of Telmisartan 80 + Amlodipine 10mg Versus Amlodipine 10 mg Monotherapy as First Line Therapy in Type 2 Diabetes Patients With Hypertension.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      To demonstrate that the fixed dose combination of telmisartan and amlodipine is more
      effective in lowering blood pressure.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Trough Seated Systolic Blood Pressure to Week 8</measure>
    <time_frame>Baseline, week 8</time_frame>
    <description>Trough blood pressure measurements were the measurements observed at the end of the dosing interval just prior to the next dose of medication.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Trough Seated Systolic Blood Pressure to Week 6</measure>
    <time_frame>Baseline, week 6</time_frame>
    <description>Trough blood pressure measurements were the measurements observed at the end of the dosing interval just prior to the next dose of medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Trough Seated Systolic Blood Pressure to Week 4</measure>
    <time_frame>Baseline, week 4</time_frame>
    <description>Trough blood pressure measurements were the measurements observed at the end of the dosing interval just prior to the next dose of medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Trough Seated Systolic Blood Pressure to Week 2</measure>
    <time_frame>Baseline, week 2</time_frame>
    <description>Trough blood pressure measurements were the measurements observed at the end of the dosing interval just prior to the next dose of medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Trough Seated Systolic Blood Pressure to Week 1</measure>
    <time_frame>Baseline, week 1</time_frame>
    <description>Trough blood pressure measurements were the measurements observed at the end of the dosing interval just prior to the next dose of medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Pressure (BP) Control (SBP&lt;140 mmHg, DBP&lt;90 mmHg) at Eight Weeks</measure>
    <time_frame>Baseline, week 8</time_frame>
    <description>Mean seated SBP&lt;140 mmHg and mean seated DBP&lt;90 mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BP Control (SBP&lt;140 mmHg, DBP&lt;90 mmHg) at Six Weeks</measure>
    <time_frame>Baseline, week 6</time_frame>
    <description>Mean seated SBP&lt;140 mmHg and mean seated DBP&lt;90 mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BP Control (SBP&lt;140 mmHg, DBP&lt;90 mmHg) at Four Weeks</measure>
    <time_frame>Baseline, week 4</time_frame>
    <description>Mean seated SBP&lt;140 mmHg and mean seated DBP&lt;90 mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BP Control (SBP&lt;140 mmHg, DBP&lt;90 mmHg) at Two Weeks</measure>
    <time_frame>Baseline, week 2</time_frame>
    <description>Mean seated SBP&lt;140 mmHg and mean seated DBP&lt;90 mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BP Control (SBP&lt;140 mmHg, DBP&lt;90 mmHg) at One Week</measure>
    <time_frame>Baseline, week 1</time_frame>
    <description>Mean seated SBP&lt;140 mmHg and mean seated DBP&lt;90 mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BP Control (SBP&lt;130 mmHg, DBP&lt;80 mmHg) at Eight Weeks</measure>
    <time_frame>Baseline, week 8</time_frame>
    <description>Mean seated SBP&lt;130 mmHg and mean seated DBP&lt;80 mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BP Control (SBP&lt;130 mmHg, DBP&lt;80 mmHg) at Six Weeks</measure>
    <time_frame>Baseline, week 6</time_frame>
    <description>Mean seated SBP&lt;130 mmHg and mean seated DBP&lt;80 mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BP Control (SBP&lt;130 mmHg, DBP&lt;80 mmHg) at Four Weeks</measure>
    <time_frame>Baseline, week 4</time_frame>
    <description>Mean seated SBP&lt;130 mmHg and mean seated DBP&lt;80 mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BP Control (SBP&lt;130 mmHg, DBP&lt;80 mmHg) at Two Weeks</measure>
    <time_frame>Baseline, week 2</time_frame>
    <description>Mean seated SBP&lt;130 mmHg and mean seated DBP&lt;80 mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BP Control (SBP&lt;130 mmHg, DBP&lt;80 mmHg) at One Week</measure>
    <time_frame>Baseline, week 1</time_frame>
    <description>Mean seated SBP&lt;130 mmHg and mean seated DBP&lt;80 mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic Blood Pressure (SBP) Control 140 at Eight Weeks</measure>
    <time_frame>Baseline, week 8</time_frame>
    <description>Mean seated SBP &lt; 140 mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SBP Control 140 at Six Weeks</measure>
    <time_frame>Baseline, week 6</time_frame>
    <description>Mean seated SBP &lt; 140 mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SBP Control 140 at Four Weeks</measure>
    <time_frame>Baseline, week 4</time_frame>
    <description>Mean seated SBP &lt; 140 mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SBP Control 140 at Two Weeks</measure>
    <time_frame>Baseline, week 2</time_frame>
    <description>Mean seated SBP &lt; 140 mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SBP Control 140 at One Week</measure>
    <time_frame>Baseline, week 1</time_frame>
    <description>Mean seated SBP &lt; 140 mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SBP Control 130 at Eight Weeks</measure>
    <time_frame>Baseline, week 8</time_frame>
    <description>Mean seated SBP &lt; 130 mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SBP Control 130 at Six Weeks</measure>
    <time_frame>Baseline, week 6</time_frame>
    <description>Mean seated SBP &lt; 130 mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SBP Control 130 at Four Weeks</measure>
    <time_frame>Baseline, week 4</time_frame>
    <description>Mean seated SBP &lt; 130 mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SBP Control 130 at Two Weeks</measure>
    <time_frame>Baseline, week 2</time_frame>
    <description>Mean seated SBP &lt; 130 mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SBP Control 130 at One Week</measure>
    <time_frame>Baseline, week 1</time_frame>
    <description>Mean seated SBP &lt; 130 mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SBP Response 140 at Eight Weeks</measure>
    <time_frame>Baseline, week 8</time_frame>
    <description>SBP &lt; 140 mmHg or a reduction &gt;=10 mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SBP Response 140 at Six Weeks</measure>
    <time_frame>Baseline, week 6</time_frame>
    <description>SBP &lt;140 mmHg or a reduction &gt;=10 mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SBP Response 140 at Four Weeks</measure>
    <time_frame>Baseline, week 4</time_frame>
    <description>SBP &lt;140 mmHg or a reduction &gt;=10 mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SBP Response 140 at Two Weeks</measure>
    <time_frame>Baseline, week 2</time_frame>
    <description>SBP &lt;140 mmHg or a reduction &gt;=10 mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SBP Response 140 at One Week</measure>
    <time_frame>Baseline, week 1</time_frame>
    <description>SBP &lt;140 mmHg or a reduction &gt;=10 mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SBP Response 130 at Eight Weeks</measure>
    <time_frame>Baseline, week 8</time_frame>
    <description>SBP &lt;130 mmHg or a reduction &gt;=10 mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SBP Response 130 at Six Weeks</measure>
    <time_frame>Baseline, week 6</time_frame>
    <description>SBP &lt;130 mmHg or a reduction &gt;=10 mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SBP Response 130 at Four Weeks</measure>
    <time_frame>Baseline, week 4</time_frame>
    <description>SBP &lt;130 mmHg or a reduction &gt;=10 mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SBP Response 130 at Two Weeks</measure>
    <time_frame>Baseline, week 2</time_frame>
    <description>SBP &lt;130 mmHg or a reduction &gt;=10 mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SBP Response 130 at One Week</measure>
    <time_frame>Baseline, week 1</time_frame>
    <description>SBP &lt;130 mmHg or a reduction &gt;=10 mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DBP Response at Eight Weeks</measure>
    <time_frame>Week 8</time_frame>
    <description>Mean seated DBP&lt;80 mmHg or a reduction of &lt;=10 mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DBP Response at Six Weeks</measure>
    <time_frame>week 6</time_frame>
    <description>Mean seated DBP&lt;80 mmHg or a reduction of &lt;=10 mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DBP Response at Week Four</measure>
    <time_frame>Week 4</time_frame>
    <description>Mean seated DBP &lt;80 mmHg or a reduction of &gt;=10 mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DBP Response at Week Two</measure>
    <time_frame>Week 2</time_frame>
    <description>Mean seated DBP &lt;80 mmHg or a reduction of &gt;=10 mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DBP Response at Week One</measure>
    <time_frame>Week 1</time_frame>
    <description>Mean seated DBP &lt;80 mmHg or a reduction of &gt;=10 mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Urine Albumin:Creatinine Ratio (UACR)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Change from baseline in UACR (measured in spot urine) after eight weeks of treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">706</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Telmisartan 80 / Amlodipine 10</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Telmisartan 80 / Amlodipine 5 for two weeks, then forced titration to Telmisartan 80 / Amlodipine 10 Fixed Dose Combination</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Amlodipine 10</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Amlodipine 5 for two weeks, then forced titration to Amlodipine 10</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telmisartan 80</intervention_name>
    <description>Telmisartan 80 mg</description>
    <arm_group_label>Telmisartan 80 / Amlodipine 10</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine 10</intervention_name>
    <description>Amlodipine 5 for two weeks, then forced titration to Amlodipine 10</description>
    <arm_group_label>Telmisartan 80 / Amlodipine 10</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine 10</intervention_name>
    <description>Amlodipine 5 for two weeks, then forced titration to Amlodipine 10</description>
    <arm_group_label>Amlodipine 10</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Hypertension defined as a mean in-clinic seated cuff Systolic Blood Pressure &gt;150 mmHg
             at Visit 3 (Randomisation visit)

          2. Diagnosis of Type 2 diabetes mellitus

          3. =18 years of age at the date of signing the informed consent

          4. Ability to stop current antihypertensive therapy without unacceptable risk to the
             patient (investigator's discretion)

          5. Ability to provide written informed consent

        Exclusion criteria:

          1. Pre-menopausal women (last menstruation &lt;=1 year prior to start of run-in period) who:

               1. are not surgically sterile; and/or

               2. are nursing or pregnant, or

               3. are of child-bearing potential and are NOT practicing acceptable means of birth
                  control or do NOT plan to continue practising an acceptable method throughout the
                  study.

             The only acceptable methods of birth control are:

               -  Intrauterine device (IUD);

               -  Oral contraceptives (started at least three months prior to start of run-in
                  period)

               -  Implantable or injectable contraceptives and

               -  Estrogen patch

          2. Night shift workers who routinely sleep during the daytime and whose work hours
             include midnight to 4:00 a.m.

          3. Known or suspected secondary hypertension (e.g., renal artery stenosis,
             phaeochromocytoma)

          4. Mean seated Systolic Blood Pressure (SBP) =180 mm Hg and/or mean seated Diastolic
             Blood Pressure (DBP) =110 mm Hg during any visit of the screening and placebo run-in
             periods

          5. Patients with Type 1 diabetes mellitus

          6. Renal dysfunction as defined by the following laboratory parameters: Serum creatinine
             &gt;3.0 mg/dL (or &gt;265 µmol /L) or known creatinine clearance &lt;30 mL/min or clinical
             markers of severe renal impairment

          7. Bilateral renal artery stenosis, renal artery stenosis in a solitary kidney,
             post-renal transplant patients or patients with only one kidney

          8. Clinically relevant hypokalaemia or hyperkalaemia

          9. Uncorrected sodium or volume depletion

         10. Primary aldosteronism

         11. Hereditary fructose intolerance

         12. Biliary obstructive disorders (e.g., cholestatis) or hepatic insufficiency

         13. Congestive heart failure New York Heart Academy (NYHA) functional class CHF III-IV
             (Refer to Appendix 10.3)

         14. Contraindication to a placebo run-in period (e.g., stroke with-in the past six months,
             myocardial infarction, cardiac surgery, percutaneous transluminal coronary
             angioplasty, unstable angina or coronary artery bypass graft within the past three
             months prior to start of run-in period)

         15. Clinically significant ventricular tachycardia, atrial fibrillation, atrial flutter or
             other clinically relevant cardiac arrhythmias as determined by the Investigator

         16. Hypertrophic obstructive cardiomyopathy, severe obstructive coronary artery disease,
             aortic stenosis, hemodynamically relevant stenosis of the aortic or mitral valve

         17. Patients whose diabetes has not been stable and controlled for at least the past three
             months as defined by an HbA1C &gt;10%

         18. Patients who have previously experienced symptoms characteristic of angioedema during
             treatment with Angiotensin Converting Enzyme (ACE) inhibitors or angiotensin-II
             receptor antagonists

         19. History of drug or alcohol dependency within six months prior to signing the informed
             consent form

         20. Concomitant administration of any medications known to affect blood pressure, except
             medications allowed by the protocol

         21. Any investigational drug therapy within one month of signing the informed consent

         22. Known hypersensitivity to any component of the study drugs (telmisartan, amlodipine,
             or placebo)

         23. History of non-compliance or inability to comply with prescribed medications or
             protocol procedures

         24. Any other clinical condition which, in the opinion of the investigator, would not
             allow safe completion of the protocol and safe administration of telmisartan and
             amlodipine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1235.21.901 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.21.907 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tustin</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.21.913 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.21.910 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.21.903 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.21.905 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tucker</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.21.916 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Olive Branch</city>
        <state>Mississippi</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.21.915 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hickory</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.21.906 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.21.902 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.21.904 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Penndel</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.21.908 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Carrollton</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.21.909 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.21.912 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Killeen</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.21.911 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ettrick</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.21.102 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Capital Federal</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.21.103 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Capital Federal</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.21.107 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ramos Mejía</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.21.101 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Santa Fe</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.21.105 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Zárate</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.21.202 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.21.201 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.21.203 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.21.204 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.21.205 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.21.302 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Acapulco</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.21.304 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Aguascalientes</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.21.301 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Guadalajara</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.21.303 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Guadalajara</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.21.305 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Guadalajara</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.21.306 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Guadalajara</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.21.408 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Beek en Donk</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.21.406 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Den Haag</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.21.401 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hoogwoud</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.21.405 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Musselkanaal</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.21.404 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nijverdal</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.21.403 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oude Pekela</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.21.409 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Roelofarensveen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.21.407 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Voerendaal</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.21.402 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wildervank</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.21.501 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.21.502 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.21.503 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.21.504 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.21.507 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dunajska Streda</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.21.509 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Martin</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.21.505 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nitra</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.21.506 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nitra</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.21.508 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rimavska Sobota</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.21.27005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.21.27007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.21.27004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Durban</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.21.27006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Johannesburg</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.21.27002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Krugersdorp</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.21.27001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lenasia</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.21.27003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pretoria</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.21.702 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Castellón</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.21.705 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Centelles</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.21.703 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sant Adrià del Besós</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.21.704 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Santa Coloma de Gramanet (Barcelona)</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.21.706 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Santa Coloma de Gramanet</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.21.801 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Göteborg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.21.803 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Helsingborg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.21.804 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lund</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.21.802 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Västerås</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Slovakia</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 6, 2009</study_first_submitted>
  <study_first_submitted_qc>April 7, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2009</study_first_posted>
  <results_first_submitted>May 13, 2011</results_first_submitted>
  <results_first_submitted_qc>May 13, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 7, 2011</results_first_posted>
  <last_update_submitted>February 10, 2014</last_update_submitted>
  <last_update_submitted_qc>February 10, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 12, 2014</last_update_posted>
  <responsible_party>
    <name_title>Boehringer Ingelheim, Study Chair</name_title>
    <organization>Boehringer Ingelheim</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telmisartan</mesh_term>
    <mesh_term>Amlodipine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Telmisartan 80 mg + Amlodipine 10 mg</title>
          <description>Once daily Telmisartan 80 mg (T80) / Amlodipine 5 mg (A5) tablet for first 2 weeks then Telmisartan 80 mg (T80) / Amlodipine 10 mg (A10) tablet for 6 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Amlodipine 10 mg</title>
          <description>Once daily Placebo / Amlodipine 5 mg (A5) tablet for first 2 weeks then Placebo / Amlodipine 10 mg (A10) tablet for 6 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="352"/>
                <participants group_id="P2" count="354"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="332"/>
                <participants group_id="P2" count="319"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="35"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other reason (not specified)</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Telmisartan 80 mg + Amlodipine 10 mg</title>
          <description>Once daily Telmisartan 80 mg (T80) / Amlodipine 5 mg (A5) tablet for first 2 weeks then Telmisartan 80 mg (T80) / Amlodipine 10 mg (A10) tablet for 6 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Amlodipine 10 mg</title>
          <description>Once daily Placebo / Amlodipine 5 mg (A5) tablet for first 2 weeks then Placebo / Amlodipine 10 mg (A10) tablet for 6 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="352"/>
            <count group_id="B2" value="354"/>
            <count group_id="B3" value="706"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.5" spread="10.4"/>
                    <measurement group_id="B2" value="60.5" spread="9.7"/>
                    <measurement group_id="B3" value="60.5" spread="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt; 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="214"/>
                    <measurement group_id="B2" value="235"/>
                    <measurement group_id="B3" value="449"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="138"/>
                    <measurement group_id="B2" value="119"/>
                    <measurement group_id="B3" value="257"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="172"/>
                    <measurement group_id="B2" value="169"/>
                    <measurement group_id="B3" value="341"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="180"/>
                    <measurement group_id="B2" value="185"/>
                    <measurement group_id="B3" value="365"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian/Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black/African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hawaiian/Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="270"/>
                    <measurement group_id="B2" value="268"/>
                    <measurement group_id="B3" value="538"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mexico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Argentina</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Republic of Korea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sweden</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slovakia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="120"/>
                    <measurement group_id="B2" value="121"/>
                    <measurement group_id="B3" value="241"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South Africa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race class</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Non-black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="309"/>
                    <measurement group_id="B2" value="313"/>
                    <measurement group_id="B3" value="622"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>centimeter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="167.1" spread="10.3"/>
                    <measurement group_id="B2" value="167.6" spread="10.9"/>
                    <measurement group_id="B3" value="167.4" spread="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kilogram</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="90.2" spread="20.9"/>
                    <measurement group_id="B2" value="89.5" spread="19.4"/>
                    <measurement group_id="B3" value="89.9" spread="20.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kilogram / square meter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.1" spread="6.0"/>
                    <measurement group_id="B2" value="31.8" spread="6.1"/>
                    <measurement group_id="B3" value="32.0" spread="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index Class</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt; 25 kg/square meter</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>25 to &lt;30 kg/square meter</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="114"/>
                    <measurement group_id="B2" value="123"/>
                    <measurement group_id="B3" value="237"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 30 kg/square meter</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="206"/>
                    <measurement group_id="B2" value="200"/>
                    <measurement group_id="B3" value="406"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking history</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Never smoked</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="221"/>
                    <measurement group_id="B2" value="222"/>
                    <measurement group_id="B3" value="443"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ex-smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="91"/>
                    <measurement group_id="B2" value="89"/>
                    <measurement group_id="B3" value="180"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Currently smokes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Alcohol history</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Non drinker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="227"/>
                    <measurement group_id="B2" value="218"/>
                    <measurement group_id="B3" value="445"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drinks - no interference</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="125"/>
                    <measurement group_id="B2" value="136"/>
                    <measurement group_id="B3" value="261"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Trough Seated Systolic Blood Pressure to Week 8</title>
        <description>Trough blood pressure measurements were the measurements observed at the end of the dosing interval just prior to the next dose of medication.</description>
        <time_frame>Baseline, week 8</time_frame>
        <population>Treated Set includes all randomized participants who took at least one dose of treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 80 mg + Amlodipine 10 mg</title>
            <description>Once daily Telmisartan 80 mg (T80) / Amlodipine 5 mg (A5) tablet for first 2 weeks then Telmisartan 80 mg (T80) / Amlodipine 10 mg (A10) tablet for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Amlodipine 10 mg</title>
            <description>Once daily Placebo / Amlodipine 5 mg (A5) tablet for first 2 weeks then Placebo / Amlodipine 10 mg (A10) tablet for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Trough Seated Systolic Blood Pressure to Week 8</title>
          <description>Trough blood pressure measurements were the measurements observed at the end of the dosing interval just prior to the next dose of medication.</description>
          <population>Treated Set includes all randomized participants who took at least one dose of treatment</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="320"/>
                <count group_id="O2" value="311"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.0" spread="0.66"/>
                    <measurement group_id="O2" value="-22.9" spread="0.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Included effects of treatment, week and treatment-by-week interaction with covariate of baseline blood pressure and baseline-week interaction.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-6.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-7.9</ci_lower_limit>
            <ci_upper_limit>-4.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Trough Seated Systolic Blood Pressure to Week 6</title>
        <description>Trough blood pressure measurements were the measurements observed at the end of the dosing interval just prior to the next dose of medication.</description>
        <time_frame>Baseline, week 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 80 mg + Amlodipine 10 mg</title>
            <description>Once daily Telmisartan 80 mg (T80) / Amlodipine 5 mg (A5) tablet for first 2 weeks then Telmisartan 80 mg (T80) / Amlodipine 10 mg (A10) tablet for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Amlodipine 10 mg</title>
            <description>Once daily Placebo / Amlodipine 5 mg (A5) tablet for first 2 weeks then Placebo / Amlodipine 10 mg (A10) tablet for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Trough Seated Systolic Blood Pressure to Week 6</title>
          <description>Trough blood pressure measurements were the measurements observed at the end of the dosing interval just prior to the next dose of medication.</description>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="326"/>
                <count group_id="O2" value="317"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.7" spread="0.62"/>
                    <measurement group_id="O2" value="-22.6" spread="0.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Included effects of treatment, week and treatment-by-week interaction with covariate of baseline blood pressure and baseline-week interaction.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-7.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-8.9</ci_lower_limit>
            <ci_upper_limit>-5.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Trough Seated Systolic Blood Pressure to Week 4</title>
        <description>Trough blood pressure measurements were the measurements observed at the end of the dosing interval just prior to the next dose of medication.</description>
        <time_frame>Baseline, week 4</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 80 mg + Amlodipine 10 mg</title>
            <description>Once daily Telmisartan 80 mg (T80) / Amlodipine 5 mg (A5) tablet for first 2 weeks then Telmisartan 80 mg (T80) / Amlodipine 10 mg (A10) tablet for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Amlodipine 10 mg</title>
            <description>Once daily Placebo / Amlodipine 5 mg (A5) tablet for first 2 weeks then Placebo / Amlodipine 10 mg (A10) tablet for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Trough Seated Systolic Blood Pressure to Week 4</title>
          <description>Trough blood pressure measurements were the measurements observed at the end of the dosing interval just prior to the next dose of medication.</description>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="329"/>
                <count group_id="O2" value="326"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.7" spread="0.62"/>
                    <measurement group_id="O2" value="-21.1" spread="0.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Included effects of treatment, week and treatment-by-week interaction with covariate of baseline blood pressure and baseline-week interaction.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-6.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-8.3</ci_lower_limit>
            <ci_upper_limit>-4.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Trough Seated Systolic Blood Pressure to Week 2</title>
        <description>Trough blood pressure measurements were the measurements observed at the end of the dosing interval just prior to the next dose of medication.</description>
        <time_frame>Baseline, week 2</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 80 mg + Amlodipine 5 mg</title>
          </group>
          <group group_id="O2">
            <title>Amlodipine 5 mg</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Trough Seated Systolic Blood Pressure to Week 2</title>
          <description>Trough blood pressure measurements were the measurements observed at the end of the dosing interval just prior to the next dose of medication.</description>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="333"/>
                <count group_id="O2" value="332"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.4" spread="0.65"/>
                    <measurement group_id="O2" value="-16.4" spread="0.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Included effects of treatment, week and treatment-by-week interaction with covariate of baseline blood pressure and baseline-week interaction.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-6.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-7.9</ci_lower_limit>
            <ci_upper_limit>-4.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Trough Seated Systolic Blood Pressure to Week 1</title>
        <description>Trough blood pressure measurements were the measurements observed at the end of the dosing interval just prior to the next dose of medication.</description>
        <time_frame>Baseline, week 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 80 mg + Amlodipine 5 mg</title>
          </group>
          <group group_id="O2">
            <title>Amlodipine 5 mg</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Trough Seated Systolic Blood Pressure to Week 1</title>
          <description>Trough blood pressure measurements were the measurements observed at the end of the dosing interval just prior to the next dose of medication.</description>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="334"/>
                <count group_id="O2" value="336"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.5" spread="0.61"/>
                    <measurement group_id="O2" value="-12.6" spread="0.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Included effects of treatment, week and treatment-by-week interaction with covariate of baseline blood pressure and baseline-week interaction.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-4.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-6.6</ci_lower_limit>
            <ci_upper_limit>-3.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Blood Pressure (BP) Control (SBP&lt;140 mmHg, DBP&lt;90 mmHg) at Eight Weeks</title>
        <description>Mean seated SBP&lt;140 mmHg and mean seated DBP&lt;90 mmHg</description>
        <time_frame>Baseline, week 8</time_frame>
        <population>Treated set using last observation carried forward (LOCF)</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 80 mg + Amlodipine 10 mg</title>
            <description>Once daily Telmisartan 80 mg (T80) / Amlodipine 5 mg (A5) tablet for first 2 weeks then Telmisartan 80 mg (T80) / Amlodipine 10 mg (A10) tablet for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Amlodipine 10 mg</title>
            <description>Once daily Placebo / Amlodipine 5 mg (A5) tablet for first 2 weeks then Placebo / Amlodipine 10 mg (A10) tablet for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Pressure (BP) Control (SBP&lt;140 mmHg, DBP&lt;90 mmHg) at Eight Weeks</title>
          <description>Mean seated SBP&lt;140 mmHg and mean seated DBP&lt;90 mmHg</description>
          <population>Treated set using last observation carried forward (LOCF)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="332"/>
                <count group_id="O2" value="329"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="237"/>
                    <measurement group_id="O2" value="177"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>BP Control (SBP&lt;140 mmHg, DBP&lt;90 mmHg) at Six Weeks</title>
        <description>Mean seated SBP&lt;140 mmHg and mean seated DBP&lt;90 mmHg</description>
        <time_frame>Baseline, week 6</time_frame>
        <population>Treated set using LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 80 mg + Amlodipine 10 mg</title>
            <description>Once daily Telmisartan 80 mg (T80) / Amlodipine 5 mg (A5) tablet for first 2 weeks then Telmisartan 80 mg (T80) / Amlodipine 10 mg (A10) tablet for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Amlodipine 10 mg</title>
            <description>Once daily Placebo / Amlodipine 5 mg (A5) tablet for first 2 weeks then Placebo / Amlodipine 10 mg (A10) tablet for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>BP Control (SBP&lt;140 mmHg, DBP&lt;90 mmHg) at Six Weeks</title>
          <description>Mean seated SBP&lt;140 mmHg and mean seated DBP&lt;90 mmHg</description>
          <population>Treated set using LOCF</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="332"/>
                <count group_id="O2" value="328"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="245"/>
                    <measurement group_id="O2" value="168"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>BP Control (SBP&lt;140 mmHg, DBP&lt;90 mmHg) at Four Weeks</title>
        <description>Mean seated SBP&lt;140 mmHg and mean seated DBP&lt;90 mmHg</description>
        <time_frame>Baseline, week 4</time_frame>
        <population>Treated set using LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 80 mg + Amlodipine 10 mg</title>
            <description>Once daily Telmisartan 80 mg (T80) / Amlodipine 5 mg (A5) tablet for first 2 weeks then Telmisartan 80 mg (T80) / Amlodipine 10 mg (A10) tablet for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Amlodipine 10 mg</title>
            <description>Once daily Placebo / Amlodipine 5 mg (A5) tablet for first 2 weeks then Placebo / Amlodipine 10 mg (A10) tablet for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>BP Control (SBP&lt;140 mmHg, DBP&lt;90 mmHg) at Four Weeks</title>
          <description>Mean seated SBP&lt;140 mmHg and mean seated DBP&lt;90 mmHg</description>
          <population>Treated set using LOCF</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="329"/>
                <count group_id="O2" value="326"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="235"/>
                    <measurement group_id="O2" value="155"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>BP Control (SBP&lt;140 mmHg, DBP&lt;90 mmHg) at Two Weeks</title>
        <description>Mean seated SBP&lt;140 mmHg and mean seated DBP&lt;90 mmHg</description>
        <time_frame>Baseline, week 2</time_frame>
        <population>Treated set using LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 80 mg + Amlodipine 5 mg</title>
            <description>Once daily Telmisartan 80 mg (T80) / Amlodipine 5 mg (A5) tablet for first 2 weeks then Telmisartan 80 mg (T80) / Amlodipine 10 mg (A10) tablet for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Amlodipine 5 mg</title>
            <description>Once daily Placebo / Amlodipine 5 mg (A5) tablet for first 2 weeks then Placebo / Amlodipine 10 mg (A10) tablet for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>BP Control (SBP&lt;140 mmHg, DBP&lt;90 mmHg) at Two Weeks</title>
          <description>Mean seated SBP&lt;140 mmHg and mean seated DBP&lt;90 mmHg</description>
          <population>Treated set using LOCF</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="337"/>
                <count group_id="O2" value="341"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="184"/>
                    <measurement group_id="O2" value="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>BP Control (SBP&lt;140 mmHg, DBP&lt;90 mmHg) at One Week</title>
        <description>Mean seated SBP&lt;140 mmHg and mean seated DBP&lt;90 mmHg</description>
        <time_frame>Baseline, week 1</time_frame>
        <population>Treated set using LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 80 mg + Amlodipine 5 mg</title>
            <description>Once daily Telmisartan 80 mg (T80) / Amlodipine 5 mg (A5) tablet for first 2 weeks then Telmisartan 80 mg (T80) / Amlodipine 10 mg (A10) tablet for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Amlodipine 5 mg</title>
            <description>Once daily Placebo / Amlodipine 5 mg (A5) tablet for first 2 weeks then Placebo / Amlodipine 10 mg (A10) tablet for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>BP Control (SBP&lt;140 mmHg, DBP&lt;90 mmHg) at One Week</title>
          <description>Mean seated SBP&lt;140 mmHg and mean seated DBP&lt;90 mmHg</description>
          <population>Treated set using LOCF</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="334"/>
                <count group_id="O2" value="336"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="130"/>
                    <measurement group_id="O2" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>BP Control (SBP&lt;130 mmHg, DBP&lt;80 mmHg) at Eight Weeks</title>
        <description>Mean seated SBP&lt;130 mmHg and mean seated DBP&lt;80 mmHg</description>
        <time_frame>Baseline, week 8</time_frame>
        <population>Treated set using LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 80 mg + Amlodipine 10 mg</title>
            <description>Once daily Telmisartan 80 mg (T80) / Amlodipine 5 mg (A5) tablet for first 2 weeks then Telmisartan 80 mg (T80) / Amlodipine 10 mg (A10) tablet for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Amlodipine 10 mg</title>
            <description>Once daily Placebo / Amlodipine 5 mg (A5) tablet for first 2 weeks then Placebo / Amlodipine 10 mg (A10) tablet for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>BP Control (SBP&lt;130 mmHg, DBP&lt;80 mmHg) at Eight Weeks</title>
          <description>Mean seated SBP&lt;130 mmHg and mean seated DBP&lt;80 mmHg</description>
          <population>Treated set using LOCF</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="332"/>
                <count group_id="O2" value="329"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="121"/>
                    <measurement group_id="O2" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>BP Control (SBP&lt;130 mmHg, DBP&lt;80 mmHg) at Six Weeks</title>
        <description>Mean seated SBP&lt;130 mmHg and mean seated DBP&lt;80 mmHg</description>
        <time_frame>Baseline, week 6</time_frame>
        <population>Treated set using LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 80 mg + Amlodipine 10 mg</title>
            <description>Once daily Telmisartan 80 mg (T80) / Amlodipine 5 mg (A5) tablet for first 2 weeks then Telmisartan 80 mg (T80) / Amlodipine 10 mg (A10) tablet for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Amlodipine 10 mg</title>
            <description>Once daily Placebo / Amlodipine 5 mg (A5) tablet for first 2 weeks then Placebo / Amlodipine 10 mg (A10) tablet for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>BP Control (SBP&lt;130 mmHg, DBP&lt;80 mmHg) at Six Weeks</title>
          <description>Mean seated SBP&lt;130 mmHg and mean seated DBP&lt;80 mmHg</description>
          <population>Treated set using LOCF</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="332"/>
                <count group_id="O2" value="328"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="134"/>
                    <measurement group_id="O2" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>BP Control (SBP&lt;130 mmHg, DBP&lt;80 mmHg) at Four Weeks</title>
        <description>Mean seated SBP&lt;130 mmHg and mean seated DBP&lt;80 mmHg</description>
        <time_frame>Baseline, week 4</time_frame>
        <population>Treated set using LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 80 mg + Amlodipine 10 mg</title>
            <description>Once daily Telmisartan 80 mg (T80) / Amlodipine 5 mg (A5) tablet for first 2 weeks then Telmisartan 80 mg (T80) / Amlodipine 10 mg (A10) tablet for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Amlodipine 10 mg</title>
            <description>Once daily Placebo / Amlodipine 5 mg (A5) tablet for first 2 weeks then Placebo / Amlodipine 10 mg (A10) tablet for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>BP Control (SBP&lt;130 mmHg, DBP&lt;80 mmHg) at Four Weeks</title>
          <description>Mean seated SBP&lt;130 mmHg and mean seated DBP&lt;80 mmHg</description>
          <population>Treated set using LOCF</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="329"/>
                <count group_id="O2" value="326"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94"/>
                    <measurement group_id="O2" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>BP Control (SBP&lt;130 mmHg, DBP&lt;80 mmHg) at Two Weeks</title>
        <description>Mean seated SBP&lt;130 mmHg and mean seated DBP&lt;80 mmHg</description>
        <time_frame>Baseline, week 2</time_frame>
        <population>Treated set using LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 80 mg + Amlodipine 5 mg</title>
            <description>Once daily Telmisartan 80 mg (T80) / Amlodipine 5 mg (A5) tablet for first 2 weeks then Telmisartan 80 mg (T80) / Amlodipine 10 mg (A10) tablet for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Amlodipine 5 mg</title>
            <description>Once daily Placebo / Amlodipine 5 mg (A5) tablet for first 2 weeks then Placebo / Amlodipine 10 mg (A10) tablet for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>BP Control (SBP&lt;130 mmHg, DBP&lt;80 mmHg) at Two Weeks</title>
          <description>Mean seated SBP&lt;130 mmHg and mean seated DBP&lt;80 mmHg</description>
          <population>Treated set using LOCF</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="337"/>
                <count group_id="O2" value="341"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>BP Control (SBP&lt;130 mmHg, DBP&lt;80 mmHg) at One Week</title>
        <description>Mean seated SBP&lt;130 mmHg and mean seated DBP&lt;80 mmHg</description>
        <time_frame>Baseline, week 1</time_frame>
        <population>Treated set using LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 80 mg + Amlodipine 5 mg</title>
            <description>Once daily Telmisartan 80 mg (T80) / Amlodipine 5 mg (A5) tablet for first 2 weeks then Telmisartan 80 mg (T80) / Amlodipine 10 mg (A10) tablet for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Amlodipine 5 mg</title>
            <description>Once daily Placebo / Amlodipine 5 mg (A5) tablet for first 2 weeks then Placebo / Amlodipine 10 mg (A10) tablet for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>BP Control (SBP&lt;130 mmHg, DBP&lt;80 mmHg) at One Week</title>
          <description>Mean seated SBP&lt;130 mmHg and mean seated DBP&lt;80 mmHg</description>
          <population>Treated set using LOCF</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="334"/>
                <count group_id="O2" value="336"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Systolic Blood Pressure (SBP) Control 140 at Eight Weeks</title>
        <description>Mean seated SBP &lt; 140 mmHg</description>
        <time_frame>Baseline, week 8</time_frame>
        <population>Treated set using LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 80 mg + Amlodipine 10 mg</title>
            <description>Once daily Telmisartan 80 mg (T80) / Amlodipine 5 mg (A5) tablet for first 2 weeks then Telmisartan 80 mg (T80) / Amlodipine 10 mg (A10) tablet for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Amlodipine 10 mg</title>
            <description>Once daily Placebo / Amlodipine 5 mg (A5) tablet for first 2 weeks then Placebo / Amlodipine 10 mg (A10) tablet for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Systolic Blood Pressure (SBP) Control 140 at Eight Weeks</title>
          <description>Mean seated SBP &lt; 140 mmHg</description>
          <population>Treated set using LOCF</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="332"/>
                <count group_id="O2" value="329"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="243"/>
                    <measurement group_id="O2" value="187"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SBP Control 140 at Six Weeks</title>
        <description>Mean seated SBP &lt; 140 mmHg</description>
        <time_frame>Baseline, week 6</time_frame>
        <population>Treated set using LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 80 mg + Amlodipine 10 mg</title>
            <description>Once daily Telmisartan 80 mg (T80) / Amlodipine 5 mg (A5) tablet for first 2 weeks then Telmisartan 80 mg (T80) / Amlodipine 10 mg (A10) tablet for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Amlodipine 10 mg</title>
            <description>Once daily Placebo / Amlodipine 5 mg (A5) tablet for first 2 weeks then Placebo / Amlodipine 10 mg (A10) tablet for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>SBP Control 140 at Six Weeks</title>
          <description>Mean seated SBP &lt; 140 mmHg</description>
          <population>Treated set using LOCF</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="332"/>
                <count group_id="O2" value="328"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="251"/>
                    <measurement group_id="O2" value="177"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SBP Control 140 at Four Weeks</title>
        <description>Mean seated SBP &lt; 140 mmHg</description>
        <time_frame>Baseline, week 4</time_frame>
        <population>Treated set using LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 80 mg + Amlodipine 10 mg</title>
            <description>Once daily Telmisartan 80 mg (T80) / Amlodipine 5 mg (A5) tablet for first 2 weeks then Telmisartan 80 mg (T80) / Amlodipine 10 mg (A10) tablet for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Amlodipine 10 mg</title>
            <description>Once daily Placebo / Amlodipine 5 mg (A5) tablet for first 2 weeks then Placebo / Amlodipine 10 mg (A10) tablet for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>SBP Control 140 at Four Weeks</title>
          <description>Mean seated SBP &lt; 140 mmHg</description>
          <population>Treated set using LOCF</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="329"/>
                <count group_id="O2" value="326"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="243"/>
                    <measurement group_id="O2" value="163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SBP Control 140 at Two Weeks</title>
        <description>Mean seated SBP &lt; 140 mmHg</description>
        <time_frame>Baseline, week 2</time_frame>
        <population>Treated set using LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 80 mg + Amlodipine 5 mg</title>
            <description>Once daily Telmisartan 80 mg (T80) / Amlodipine 5 mg (A5) tablet for first 2 weeks then Telmisartan 80 mg (T80) / Amlodipine 10 mg (A10) tablet for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Amlodipine 5 mg</title>
            <description>Once daily Placebo / Amlodipine 5 mg (A5) tablet for first 2 weeks then Placebo / Amlodipine 10 mg (A10) tablet for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>SBP Control 140 at Two Weeks</title>
          <description>Mean seated SBP &lt; 140 mmHg</description>
          <population>Treated set using LOCF</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="337"/>
                <count group_id="O2" value="341"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="193"/>
                    <measurement group_id="O2" value="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SBP Control 140 at One Week</title>
        <description>Mean seated SBP &lt; 140 mmHg</description>
        <time_frame>Baseline, week 1</time_frame>
        <population>Treated set using LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 80 mg + Amlodipine 5 mg</title>
            <description>Once daily Telmisartan 80 mg (T80) / Amlodipine 5 mg (A5) tablet for first 2 weeks then Telmisartan 80 mg (T80) / Amlodipine 10 mg (A10) tablet for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Amlodipine 5 mg</title>
            <description>Once daily Placebo / Amlodipine 5 mg (A5) tablet for first 2 weeks then Placebo / Amlodipine 10 mg (A10) tablet for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>SBP Control 140 at One Week</title>
          <description>Mean seated SBP &lt; 140 mmHg</description>
          <population>Treated set using LOCF</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="334"/>
                <count group_id="O2" value="336"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="141"/>
                    <measurement group_id="O2" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SBP Control 130 at Eight Weeks</title>
        <description>Mean seated SBP &lt; 130 mmHg</description>
        <time_frame>Baseline, week 8</time_frame>
        <population>Treated set using LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 80 mg + Amlodipine 10 mg</title>
            <description>Once daily Telmisartan 80 mg (T80) / Amlodipine 5 mg (A5) tablet for first 2 weeks then Telmisartan 80 mg (T80) / Amlodipine 10 mg (A10) tablet for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Amlodipine 10 mg</title>
            <description>Once daily Placebo / Amlodipine 5 mg (A5) tablet for first 2 weeks then Placebo / Amlodipine 10 mg (A10) tablet for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>SBP Control 130 at Eight Weeks</title>
          <description>Mean seated SBP &lt; 130 mmHg</description>
          <population>Treated set using LOCF</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="332"/>
                <count group_id="O2" value="329"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="157"/>
                    <measurement group_id="O2" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SBP Control 130 at Six Weeks</title>
        <description>Mean seated SBP &lt; 130 mmHg</description>
        <time_frame>Baseline, week 6</time_frame>
        <population>Treated set using LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 80 mg + Amlodipine 10 mg</title>
            <description>Once daily Telmisartan 80 mg (T80) / Amlodipine 5 mg (A5) tablet for first 2 weeks then Telmisartan 80 mg (T80) / Amlodipine 10 mg (A10) tablet for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Amlodipine 10 mg</title>
            <description>Once daily Placebo / Amlodipine 5 mg (A5) tablet for first 2 weeks then Placebo / Amlodipine 10 mg (A10) tablet for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>SBP Control 130 at Six Weeks</title>
          <description>Mean seated SBP &lt; 130 mmHg</description>
          <population>Treated set using LOCF</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="332"/>
                <count group_id="O2" value="328"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="164"/>
                    <measurement group_id="O2" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SBP Control 130 at Four Weeks</title>
        <description>Mean seated SBP &lt; 130 mmHg</description>
        <time_frame>Baseline, week 4</time_frame>
        <population>Treated set using LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 80 mg + Amlodipine 10 mg</title>
            <description>Once daily Telmisartan 80 mg (T80) / Amlodipine 5 mg (A5) tablet for first 2 weeks then Telmisartan 80 mg (T80) / Amlodipine 10 mg (A10) tablet for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Amlodipine 10 mg</title>
            <description>Once daily Placebo / Amlodipine 5 mg (A5) tablet for first 2 weeks then Placebo / Amlodipine 10 mg (A10) tablet for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>SBP Control 130 at Four Weeks</title>
          <description>Mean seated SBP &lt; 130 mmHg</description>
          <population>Treated set using LOCF</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="329"/>
                <count group_id="O2" value="326"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="137"/>
                    <measurement group_id="O2" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SBP Control 130 at Two Weeks</title>
        <description>Mean seated SBP &lt; 130 mmHg</description>
        <time_frame>Baseline, week 2</time_frame>
        <population>Treated set using LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 80 mg + Amlodipine 5 mg</title>
            <description>Once daily Telmisartan 80 mg (T80) / Amlodipine 5 mg (A5) tablet for first 2 weeks then Telmisartan 80 mg (T80) / Amlodipine 10 mg (A10) tablet for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Amlodipine 5 mg</title>
            <description>Once daily Placebo / Amlodipine 5 mg (A5) tablet for first 2 weeks then Placebo / Amlodipine 10 mg (A10) tablet for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>SBP Control 130 at Two Weeks</title>
          <description>Mean seated SBP &lt; 130 mmHg</description>
          <population>Treated set using LOCF</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="337"/>
                <count group_id="O2" value="341"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92"/>
                    <measurement group_id="O2" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SBP Control 130 at One Week</title>
        <description>Mean seated SBP &lt; 130 mmHg</description>
        <time_frame>Baseline, week 1</time_frame>
        <population>Treated set using LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 80 mg + Amlodipine 5 mg</title>
            <description>Once daily Telmisartan 80 mg (T80) / Amlodipine 5 mg (A5) tablet for first 2 weeks then Telmisartan 80 mg (T80) / Amlodipine 10 mg (A10) tablet for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Amlodipine 5 mg</title>
            <description>Once daily Placebo / Amlodipine 5 mg (A5) tablet for first 2 weeks then Placebo / Amlodipine 10 mg (A10) tablet for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>SBP Control 130 at One Week</title>
          <description>Mean seated SBP &lt; 130 mmHg</description>
          <population>Treated set using LOCF</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="334"/>
                <count group_id="O2" value="336"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SBP Response 140 at Eight Weeks</title>
        <description>SBP &lt; 140 mmHg or a reduction &gt;=10 mmHg</description>
        <time_frame>Baseline, week 8</time_frame>
        <population>Treated set using LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 80 mg + Amlodipine 10 mg</title>
            <description>Once daily Telmisartan 80 mg (T80) / Amlodipine 5 mg (A5) tablet for first 2 weeks then Telmisartan 80 mg (T80) / Amlodipine 10 mg (A10) tablet for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Amlodipine 10 mg</title>
            <description>Once daily Placebo / Amlodipine 5 mg (A5) tablet for first 2 weeks then Placebo / Amlodipine 10 mg (A10) tablet for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>SBP Response 140 at Eight Weeks</title>
          <description>SBP &lt; 140 mmHg or a reduction &gt;=10 mmHg</description>
          <population>Treated set using LOCF</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="332"/>
                <count group_id="O2" value="329"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="309"/>
                    <measurement group_id="O2" value="288"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SBP Response 140 at Six Weeks</title>
        <description>SBP &lt;140 mmHg or a reduction &gt;=10 mmHg</description>
        <time_frame>Baseline, week 6</time_frame>
        <population>Treated set using LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 80 mg + Amlodipine 10 mg</title>
            <description>Once daily Telmisartan 80 mg (T80) / Amlodipine 5 mg (A5) tablet for first 2 weeks then Telmisartan 80 mg (T80) / Amlodipine 10 mg (A10) tablet for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Amlodipine 10 mg</title>
            <description>Once daily Placebo / Amlodipine 5 mg (A5) tablet for first 2 weeks then Placebo / Amlodipine 10 mg (A10) tablet for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>SBP Response 140 at Six Weeks</title>
          <description>SBP &lt;140 mmHg or a reduction &gt;=10 mmHg</description>
          <population>Treated set using LOCF</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="332"/>
                <count group_id="O2" value="328"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="318"/>
                    <measurement group_id="O2" value="286"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SBP Response 140 at Four Weeks</title>
        <description>SBP &lt;140 mmHg or a reduction &gt;=10 mmHg</description>
        <time_frame>Baseline, week 4</time_frame>
        <population>Treated set using LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 80 mg + Amlodipine 10 mg</title>
            <description>Once daily Telmisartan 80 mg (T80) / Amlodipine 5 mg (A5) tablet for first 2 weeks then Telmisartan 80 mg (T80) / Amlodipine 10 mg (A10) tablet for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Amlodipine 10 mg</title>
            <description>Once daily Placebo / Amlodipine 5 mg (A5) tablet for first 2 weeks then Placebo / Amlodipine 10 mg (A10) tablet for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>SBP Response 140 at Four Weeks</title>
          <description>SBP &lt;140 mmHg or a reduction &gt;=10 mmHg</description>
          <population>Treated set using LOCF</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="329"/>
                <count group_id="O2" value="326"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="309"/>
                    <measurement group_id="O2" value="274"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SBP Response 140 at Two Weeks</title>
        <description>SBP &lt;140 mmHg or a reduction &gt;=10 mmHg</description>
        <time_frame>Baseline, week 2</time_frame>
        <population>Treated set using LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 80 mg + Amlodipine 5 mg</title>
            <description>Once daily Telmisartan 80 mg (T80) / Amlodipine 5 mg (A5) tablet for first 2 weeks then Telmisartan 80 mg (T80) / Amlodipine 10 mg (A10) tablet for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Amlodipine 5 mg</title>
            <description>Once daily Placebo / Amlodipine 5 mg (A5) tablet for first 2 weeks then Placebo / Amlodipine 10 mg (A10) tablet for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>SBP Response 140 at Two Weeks</title>
          <description>SBP &lt;140 mmHg or a reduction &gt;=10 mmHg</description>
          <population>Treated set using LOCF</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="337"/>
                <count group_id="O2" value="341"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="297"/>
                    <measurement group_id="O2" value="246"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SBP Response 140 at One Week</title>
        <description>SBP &lt;140 mmHg or a reduction &gt;=10 mmHg</description>
        <time_frame>Baseline, week 1</time_frame>
        <population>Treated set using LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 80 mg + Amlodipine 5 mg</title>
            <description>Once daily Telmisartan 80 mg (T80) / Amlodipine 5 mg (A5) tablet for first 2 weeks then Telmisartan 80 mg (T80) / Amlodipine 10 mg (A10) tablet for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Amlodipine 5 mg</title>
            <description>Once daily Placebo / Amlodipine 5 mg (A5) tablet for first 2 weeks then Placebo / Amlodipine 10 mg (A10) tablet for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>SBP Response 140 at One Week</title>
          <description>SBP &lt;140 mmHg or a reduction &gt;=10 mmHg</description>
          <population>Treated set using LOCF</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="334"/>
                <count group_id="O2" value="336"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="253"/>
                    <measurement group_id="O2" value="201"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SBP Response 130 at Eight Weeks</title>
        <description>SBP &lt;130 mmHg or a reduction &gt;=10 mmHg</description>
        <time_frame>Baseline, week 8</time_frame>
        <population>Treated set using LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 80 mg + Amlodipine 10 mg</title>
            <description>Once daily Telmisartan 80 mg (T80) / Amlodipine 5 mg (A5) tablet for first 2 weeks then Telmisartan 80 mg (T80) / Amlodipine 10 mg (A10) tablet for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Amlodipine 10 mg</title>
            <description>Once daily Placebo / Amlodipine 5 mg (A5) tablet for first 2 weeks then Placebo / Amlodipine 10 mg (A10) tablet for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>SBP Response 130 at Eight Weeks</title>
          <description>SBP &lt;130 mmHg or a reduction &gt;=10 mmHg</description>
          <population>Treated set using LOCF</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="332"/>
                <count group_id="O2" value="329"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="309"/>
                    <measurement group_id="O2" value="288"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SBP Response 130 at Six Weeks</title>
        <description>SBP &lt;130 mmHg or a reduction &gt;=10 mmHg</description>
        <time_frame>Baseline, week 6</time_frame>
        <population>Treated set using LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 80 mg + Amlodipine 10 mg</title>
            <description>Once daily Telmisartan 80 mg (T80) / Amlodipine 5 mg (A5) tablet for first 2 weeks then Telmisartan 80 mg (T80) / Amlodipine 10 mg (A10) tablet for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Amlodipine 10 mg</title>
            <description>Once daily Placebo / Amlodipine 5 mg (A5) tablet for first 2 weeks then Placebo / Amlodipine 10 mg (A10) tablet for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>SBP Response 130 at Six Weeks</title>
          <description>SBP &lt;130 mmHg or a reduction &gt;=10 mmHg</description>
          <population>Treated set using LOCF</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="332"/>
                <count group_id="O2" value="328"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="318"/>
                    <measurement group_id="O2" value="286"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SBP Response 130 at Four Weeks</title>
        <description>SBP &lt;130 mmHg or a reduction &gt;=10 mmHg</description>
        <time_frame>Baseline, week 4</time_frame>
        <population>Treated set using LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 80 mg + Amlodipine 10 mg</title>
            <description>Once daily Telmisartan 80 mg (T80) / Amlodipine 5 mg (A5) tablet for first 2 weeks then Telmisartan 80 mg (T80) / Amlodipine 10 mg (A10) tablet for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Amlodipine 10 mg</title>
            <description>Once daily Placebo / Amlodipine 5 mg (A5) tablet for first 2 weeks then Placebo / Amlodipine 10 mg (A10) tablet for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>SBP Response 130 at Four Weeks</title>
          <description>SBP &lt;130 mmHg or a reduction &gt;=10 mmHg</description>
          <population>Treated set using LOCF</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="329"/>
                <count group_id="O2" value="326"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="309"/>
                    <measurement group_id="O2" value="274"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SBP Response 130 at Two Weeks</title>
        <description>SBP &lt;130 mmHg or a reduction &gt;=10 mmHg</description>
        <time_frame>Baseline, week 2</time_frame>
        <population>Treated set using LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 80 mg + Amlodipine 5 mg</title>
            <description>Once daily Telmisartan 80 mg (T80) / Amlodipine 5 mg (A5) tablet for first 2 weeks then Telmisartan 80 mg (T80) / Amlodipine 10 mg (A10) tablet for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Amlodipine 5 mg</title>
            <description>Once daily Placebo / Amlodipine 5 mg (A5) tablet for first 2 weeks then Placebo / Amlodipine 10 mg (A10) tablet for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>SBP Response 130 at Two Weeks</title>
          <description>SBP &lt;130 mmHg or a reduction &gt;=10 mmHg</description>
          <population>Treated set using LOCF</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="337"/>
                <count group_id="O2" value="341"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="297"/>
                    <measurement group_id="O2" value="246"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SBP Response 130 at One Week</title>
        <description>SBP &lt;130 mmHg or a reduction &gt;=10 mmHg</description>
        <time_frame>Baseline, week 1</time_frame>
        <population>Treated set using LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 80 mg + Amlodipine 5 mg</title>
            <description>Once daily Telmisartan 80 mg (T80) / Amlodipine 5 mg (A5) tablet for first 2 weeks then Telmisartan 80 mg (T80) / Amlodipine 10 mg (A10) tablet for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Amlodipine 5 mg</title>
            <description>Once daily Placebo / Amlodipine 5 mg (A5) tablet for first 2 weeks then Placebo / Amlodipine 10 mg (A10) tablet for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>SBP Response 130 at One Week</title>
          <description>SBP &lt;130 mmHg or a reduction &gt;=10 mmHg</description>
          <population>Treated set using LOCF</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="334"/>
                <count group_id="O2" value="336"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="253"/>
                    <measurement group_id="O2" value="199"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>DBP Response at Eight Weeks</title>
        <description>Mean seated DBP&lt;80 mmHg or a reduction of &lt;=10 mmHg</description>
        <time_frame>Week 8</time_frame>
        <population>Treated set</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 80 mg + Amlodipine 10 mg</title>
            <description>Once daily Telmisartan 80 mg (T80) / Amlodipine 5 mg (A5) tablet for first 2 weeks then Telmisartan 80 mg (T80) / Amlodipine 10 mg (A10) tablet for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Amlodipine 10 mg</title>
            <description>Once daily Placebo / Amlodipine 5 mg (A5) tablet for first 2 weeks then Placebo / Amlodipine 10 mg (A10) tablet for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>DBP Response at Eight Weeks</title>
          <description>Mean seated DBP&lt;80 mmHg or a reduction of &lt;=10 mmHg</description>
          <population>Treated set</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="332"/>
                <count group_id="O2" value="329"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="253"/>
                    <measurement group_id="O2" value="214"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>DBP Response at Six Weeks</title>
        <description>Mean seated DBP&lt;80 mmHg or a reduction of &lt;=10 mmHg</description>
        <time_frame>week 6</time_frame>
        <population>Treated set</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 80 mg + Amlodipine 10 mg</title>
            <description>Once daily Telmisartan 80 mg (T80) / Amlodipine 5 mg (A5) tablet for first 2 weeks then Telmisartan 80 mg (T80) / Amlodipine 10 mg (A10) tablet for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Amlodipine 10 mg</title>
            <description>Once daily Placebo / Amlodipine 5 mg (A5) tablet for first 2 weeks then Placebo / Amlodipine 10 mg (A10) tablet for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>DBP Response at Six Weeks</title>
          <description>Mean seated DBP&lt;80 mmHg or a reduction of &lt;=10 mmHg</description>
          <population>Treated set</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="332"/>
                <count group_id="O2" value="328"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="275"/>
                    <measurement group_id="O2" value="214"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>DBP Response at Week Four</title>
        <description>Mean seated DBP &lt;80 mmHg or a reduction of &gt;=10 mmHg</description>
        <time_frame>Week 4</time_frame>
        <population>Treated set</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 80 mg + Amlodipine 10 mg</title>
            <description>Once daily Telmisartan 80 mg (T80) / Amlodipine 5 mg (A5) tablet for first 2 weeks then Telmisartan 80 mg (T80) / Amlodipine 10 mg (A10) tablet for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Amlodipine 10 mg</title>
            <description>Once daily Placebo / Amlodipine 5 mg (A5) tablet for first 2 weeks then Placebo / Amlodipine 10 mg (A10) tablet for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>DBP Response at Week Four</title>
          <description>Mean seated DBP &lt;80 mmHg or a reduction of &gt;=10 mmHg</description>
          <population>Treated set</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="329"/>
                <count group_id="O2" value="326"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="250"/>
                    <measurement group_id="O2" value="190"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>DBP Response at Week Two</title>
        <description>Mean seated DBP &lt;80 mmHg or a reduction of &gt;=10 mmHg</description>
        <time_frame>Week 2</time_frame>
        <population>Treated set</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 80 mg + Amlodipine 5 mg</title>
            <description>Once daily Telmisartan 80 mg (T80) / Amlodipine 5 mg (A5) tablet for first 2 weeks then Telmisartan 80 mg (T80) / Amlodipine 10 mg (A10) tablet for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Amlodipine 5 mg</title>
            <description>Once daily Placebo / Amlodipine 5 mg (A5) tablet for first 2 weeks then Placebo / Amlodipine 10 mg (A10) tablet for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>DBP Response at Week Two</title>
          <description>Mean seated DBP &lt;80 mmHg or a reduction of &gt;=10 mmHg</description>
          <population>Treated set</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="337"/>
                <count group_id="O2" value="341"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="206"/>
                    <measurement group_id="O2" value="166"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>DBP Response at Week One</title>
        <description>Mean seated DBP &lt;80 mmHg or a reduction of &gt;=10 mmHg</description>
        <time_frame>Week 1</time_frame>
        <population>Treated set</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 80 mg + Amlodipine 5 mg</title>
            <description>Once daily Telmisartan 80 mg (T80) / Amlodipine 5 mg (A5) tablet for first 2 weeks then Telmisartan 80 mg (T80) / Amlodipine 10 mg (A10) tablet for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Amlodipine 5 mg</title>
            <description>Once daily Placebo / Amlodipine 5 mg (A5) tablet for first 2 weeks then Placebo / Amlodipine 10 mg (A10) tablet for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>DBP Response at Week One</title>
          <description>Mean seated DBP &lt;80 mmHg or a reduction of &gt;=10 mmHg</description>
          <population>Treated set</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="334"/>
                <count group_id="O2" value="336"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="165"/>
                    <measurement group_id="O2" value="113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Urine Albumin:Creatinine Ratio (UACR)</title>
        <description>Change from baseline in UACR (measured in spot urine) after eight weeks of treatment</description>
        <time_frame>8 weeks</time_frame>
        <population>Treated set</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 80 mg + Amlodipine 10 mg</title>
            <description>Once daily Telmisartan 80 mg (T80) / Amlodipine 5 mg (A5) tablet for first 2 weeks then Telmisartan 80 mg (T80) / Amlodipine 10 mg (A10) tablet for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Amlodipine 10 mg</title>
            <description>Once daily Placebo / Amlodipine 5 mg (A5) tablet for first 2 weeks then Placebo / Amlodipine 10 mg (A10) tablet for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Urine Albumin:Creatinine Ratio (UACR)</title>
          <description>Change from baseline in UACR (measured in spot urine) after eight weeks of treatment</description>
          <population>Treated set</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="334"/>
                <count group_id="O2" value="333"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.36" spread="0.79"/>
                    <measurement group_id="O2" value="0.04" spread="0.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Telmisartan 80 mg + Amlodipine 10 mg</title>
          <description>Once daily Telmisartan 80 mg (T80) / Amlodipine 5 mg (A5) tablet for first 2 weeks then Telmisartan 80 mg (T80) / Amlodipine 10 mg (A10) tablet for 6 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Amlodipine 10 mg</title>
          <description>Once daily Placebo / Amlodipine 5 mg (A5) tablet for first 2 weeks then Placebo / Amlodipine 10 mg (A10) tablet for 6 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA version 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="352"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="354"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="354"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="354"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="354"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="354"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatitis alcoholic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="354"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="354"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="354"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="354"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="354"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="354"/>
              </event>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="354"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="354"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (13.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="352"/>
                <counts group_id="E2" subjects_affected="71" subjects_at_risk="354"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="352"/>
                <counts group_id="E2" subjects_affected="71" subjects_at_risk="354"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

